ArticleJournal of Cancer2016
Reduced Expression of FADS1 Predicts Worse Prognosis in Non-Small-Cell Lung Cancer.
Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Causal inference of glucocorticoid signaling in non-small cell lung cancer: integrating Mendelian randomization, single-cell transcriptomics, and imaging data.NPJ precision oncology · 2026Article
- Machine learning-based proteogenomic data modeling identifies circulating plasma biomarkers for early detection of lung cancer.Communications medicine · 2026Article
- Identification of Bone Metastasis-Related Gene Networks in Lung Cancer: Implications for Bone Metabolism.Journal of bone metabolism · 2025Article
- Tumor immune microenvironment delineates progression trajectories of distinct nasopharyngeal carcinoma phenotypes.Cell reports. Medicine · 2025Article
- Nutrigenetics and Omega-3 and Gamma-Linolenic Acid Intake and Status in Patients with Cancer: A PRISMA Scoping Review of Research Trends and Challenges.International journal of molecular sciences · 2025Article
- FADS1, a lipid metabolism-related diagnostic biomarker in KIRC.Discover oncology · 2025Article
- Study on Potential Differentially Expressed Genes in Idiopathic Pulmonary Fibrosis by Bioinformatics and Next-Generation Sequencing Data Analysis.Biomedicines · 2023Article
- Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation.Frontiers in immunology · 2023Article
- LncRNA LINC01569 promotes M2 macrophage polarization to accelerate hypopharyngeal carcinoma progression through the miR-193a-5p/FADS1 signaling axis.Journal of Cancer · 2023Article
- Fatty acid desaturase 1 (FADS1) is a cancer marker for patient survival and a potential novel target for precision cancer treatment.Frontiers in oncology · 2022Article
- Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.Lipids in health and disease · 2021Article
- The diversity and breadth of cancer cell fatty acid metabolism.Cancer & metabolism · 2021Review
- Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma.Cancer medicine · 2020Article
- Expression ofBiomolecules · 2020Article
- Identification of FADS1 Through Common Gene Expression Profiles for Predicting Survival in Patients with Bladder Cancer.Cancer management and research · 2020Article
- Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment.Frontiers in oncology · 2020Review
- Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFatty acid desaturase 1 is a member of the fatty acid desaturase, which is related to a number of diseases. However, its role in cancers remains unclear. This study was to explore the clinical importance of FADS1 expression in non-small-cell lung cancer (NSCLC). MATERIALS AND
methodsImmunochemistry was used to evaluate FADS1 expressions in 216 paraffin-embedded specimens. The expression of FADS1 was divided into high and low groups. The clinical and prognostic significance of FADS1 expression was analyzed statistically by Kaplan-Meier estimate and Cox regression model.
resultsFADS1 overexpressed in normal bronchial mucosa compared with non-small-cell lung cancer. Reduced FADS1 expression was associated with tumor size (P=0.023) and histological grade (P<0.0001). Patients with lower expression of FADS1 had shorter overall survival and disease free survival (P=0.001 and P=0.002). Multivariate analysis showed FADS1 expression was an independent prognostic factor in NSCLC (P=0.011).
conclusionReduced expression of FADS1 suggests pessimistic prognosis for NSCLC patients. Further studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.